--- arxiv_id: PMC12937832 title: "Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms." authors: - Faryal B - Ul Abideen Z - Irfan M - Ahmed H - Jalilov F - Abduraximova L - Ashraf GA difficulty: Advanced tags: - Oncology - PROTAC published_at: 2026 Feb 1 flecto_url: https://flecto.zer0ai.dev/papers/PMC12937832/ lang: en --- > A comprehensive review of how PROTACs are revolutionizing cancer treatment by selectively degrading disease-causing proteins through the ubiquitin-proteasome system **Authors**: Bushra Faryal, Zain Ul Abideen, Muhammad Irfan, Haseeb Ahmed, Fazliddin Jalilov, Lola Abduraximova & Ghulam Mustafa — Biomolecules , 2026 ## Abstract ### Abstract The onset of proteolysis targeting chimeras (PROTACs) has reshaped the entire context of targeted cancer therapy by offering a novel approach for the selective degradation of disease-causing proteins, overcoming the limitations of traditional occupancy-driven inhibition. This heterobifunctional technology recruits endogenous E3 ubiquitin ligases to mark proteins of interest (POI) for proteasomal degradation via the ubiquitin-proteasome system (UPS) . Unlike conventional inhibitors, PROTACs function catalytically and can target previously "undruggable" proteins, such as transcription factors, scaffold proteins, and non-enzymatic regulators, offering potential to overcome acquired resistance and achieve potent efficacy at sub-stoichiometric doses. This review explores the latest innovations in PROTAC design, promising clinical candidates, translational challenges, and emerging modalities like AUTACs/ATTECs, LYTACs , and AI-driven design approaches. ### PROTACs in Clinical Trials ### E3 Ligases in Human Genome ### Scientific Figures ### Major Sections Covered ## Introduction ### Introduction Despite recent breakthroughs, cancer remains a leading cause of morbidity and mortality worldwide , with approximately 20 million new cases and 9.7 million deaths reported globally in 2020, and projections of 35 million new cases by 2050. The most common cancers, including breast, lung, and colorectal cancers, pose significant challenges due to limitations in treatment access and therapeutic resistance. Traditional small-molecule drugs work by occupying the active site of a target protein to block its function. However, this approach has a fundamental limitation: only about 20% of the human proteome is considered "druggable" by conventional methods. Many disease-driving proteins, such as transcription factors, scaffold proteins, and non-enzymatic regulators, lack well-defined binding pockets for traditional drugs. PROTACs represent a paradigm shift by degrading target proteins rather than merely inhibiting them . These bifunctional molecules simultaneously bind a target protein and an E3 ubiquitin ligase, bringing them into proximity and triggering the cell's own protein disposal machinery. Because PROTACs act catalytically , a single PROTAC molecule can destroy multiple copies of its target, achieving potent effects at very low doses. This "event-driven" pharmacology also means PROTACs can overcome many resistance mechanisms that limit traditional inhibitors. ## References ### References This review article cites over 100 references. For the full reference list, please refer to the original paper on PMC. ## Protac Design ### Overview of PROTAC Design ### Mechanism of Action PROTACs consist of three essential structural components : a ligand that binds to the protein of interest (POI), a ligand that recruits an E3 ubiquitin ligase, and a chemical linker connecting them. When the PROTAC bridges the POI and E3 ligase, it forms a ternary complex that triggers ubiquitin transfer. The polyubiquitinated target is then recognized and degraded by the 26S proteasome. Crucially, the PROTAC itself is recycled after degradation, allowing it to engage additional target molecules in a catalytic fashion. Figure 1: PROTAC mechanism of action cycle showing target binding, ternary complex formation, ubiquitination, proteasomal degradation, and PROTAC recycling. Figure 2: Ternary complex as a decision node (A), degradation as a threshold process (B), and biological constraints on PROTAC design (C). Figure 3: The E1-E2-E3 enzymatic cascade in the ubiquitin-proteasome system, showing how PROTACs hijack this machinery for targeted protein degradation. ### PROTACs vs. Traditional Inhibitors Traditional small-molecule inhibitors face several key limitations: they cannot target proteins without active sites, they have off-target effects, they achieve incomplete inhibition, and they are susceptible to resistance mutations. PROTACs overcome these by degrading the entire protein rather than simply blocking one function. Because degradation eliminates both enzymatic and scaffolding functions of the target, PROTACs can address targets and resistance mechanisms that inhibitors cannot. Figure 4: Comparison of traditional inhibitor limitations (a) vs. PROTAC catalytic degradation mechanism (b). Table 1: Head-to-head comparison of PROTACs versus traditional small-molecule inhibitors across key pharmacological parameters. ### Role of E3 Ligases in PROTAC Design The human genome encodes approximately 600 E3 ubiquitin ligases , yet current PROTAC technology primarily exploits only two: CRBN (cereblon) and VHL (Von Hippel-Lindau) . These two account for the vast majority of PROTACs in development. Expanding the E3 ligase toolbox is critical to broaden tissue selectivity, reduce off-target degradation, and overcome resistance arising from ligase downregulation. Emerging E3 ligase targets include KEAP1, MDM2, XIAP, RNF4, and BIRC2, discovered through chemical proteomics and computational approaches. ### Recent Innovations in PROTAC Design The PROTAC field has seen rapid innovation in linker chemistry, spatial/temporal control, and delivery systems: Photo-PROTACs: Light-activatable PROTACs that enable spatiotemporal control of protein degradation, reducing off-target effects in healthy tissues. Click-PROTACs: In-cell assembly of PROTAC components using bioorthogonal click chemistry, enabling tumor-selective activation. Folate-caged PROTACs: Tumor-targeting PROTACs that activate only in cancer cells expressing folate receptors, improving therapeutic window. Covalent PROTACs: Irreversible binding to either the target or E3 ligase for enhanced potency and sustained degradation. ## Clinical ### Clinical Landscape and Trials PROTACs have rapidly advanced from academic curiosity to clinical reality. Multiple candidates are now in Phase I/II clinical trials, with ARV-110 and ARV-471 leading the field. The development timeline spans from the serendipitous discovery of thalidomide's effects in the 1950s-60s through the identification of cereblon as an E3 ligase substrate in the 2000s, to the current maturity era of clinical validation. Figure 5: Comprehensive timeline of PROTAC development from the 1950s (thalidomide discovery) to 2024 (Phase IV trials and next-generation formats). Figure 6: Three eras of PROTAC development: Tinkering Era (initial discovery), Repurposing Era (clinical repositioning), and Maturity Era (clinical validation). ### Clinical PROTACs vs. Standard of Care Five leading PROTAC candidates are being compared head-to-head with existing treatments. ARV-110 shows superior PSA50 response rates (~46%) versus enzalutamide ( ARV-471 achieves ~40% clinical benefit rate with oral bioavailability versus fulvestrant's injection requirement. DT2216 avoids the dose-limiting thrombocytopenia that plagues navitoclax by exploiting VHL's low expression in platelets. ### Table 2: Comparative efficacy data for clinical PROTACs versus current standard of care treatments. ### ARV-110, DT2216, and ARV-471 ARV-110 is an androgen receptor (AR) degrader for metastatic castration-resistant prostate cancer (mCRPC). It recruits CRBN to ubiquitinate and degrade AR, overcoming common resistance mutations (T878A, H875Y). DT2216 targets BCL-xL, a key anti-apoptotic protein, using VHL as the E3 ligase. Its tissue selectivity spares platelets (which have low VHL expression), avoiding thrombocytopenia. ARV-471 degrades estrogen receptor alpha (ERα) for ER-positive breast cancer, achieving >90% ER degradation with oral bioavailability. Figure 7: Mechanisms of three key clinical PROTACs: ARV-110 (AR degrader, prostate cancer), DT2216 (BCL-xL degrader, platelet-sparing), and ARV-471 (ER degrader, breast cancer). ### KT-474: IRAK4 Degrader KT-474 is a VHL-recruiting PROTAC that degrades IRAK4 (interleukin-1 receptor-associated kinase 4), a key mediator of innate immune signaling. Unlike kinase inhibitors that only block IRAK4's enzymatic activity, KT-474 eliminates both kinase and scaffold functions , providing more complete pathway suppression in immuno-inflammatory cancers. Figure 8: KT-474 mechanism of action in the IL-1R/TLR signaling pathway, showing IRAK4 degradation via VHL recruitment. ### NX-2127: Dual BTK/IKZF1/3 Degrader NX-2127 represents a new paradigm in PROTAC design: dual-target degradation . It simultaneously degrades BTK (Bruton's tyrosine kinase) and the transcription factors IKZF1/IKZF3 (Ikaros/Aiolos). This dual action directly kills malignant B cells via BTK degradation while also activating anti-tumor T-cell immunity through IKZF1/3 depletion. NX-2127 overcomes resistance to covalent BTK inhibitors (ibrutinib) by degrading the entire protein rather than depending on a specific binding site. Figure 9: NX-2127 dual mechanism: simultaneous BTK and IKZF1/3 degradation targeting both malignant B cells and activating anti-tumor T cell immunity. Figure 10: BTK inhibitor resistance mutations across enzymatic classes and how NX-2127 overcomes them by degrading the whole protein, with Phase 1 clinical data. ## Challenges ### Challenges and Limitations Despite their promise, PROTACs face several significant hurdles on the path to widespread clinical adoption. Understanding these challenges is essential for designing next-generation degraders that can overcome current limitations. Figure 11: Side-by-side comparison of PROTAC advantages (catalytic action, low dose efficacy, resistance overcome, undruggable target access) and challenges (molecular weight, bioavailability, off-target degradation, manufacturing cost). ### Pharmacokinetics & Bioavailability PROTACs are large molecules (typically >700 Da) that violate Lipinski's Rule of Five, leading to poor oral absorption, low membrane permeability, and rapid metabolic clearance. Strategies to address this include macrocyclization, prodrug approaches, and nano-formulations. ### E3 Ligase Availability Most PROTACs rely on CRBN or VHL, but these ligases have tissue-specific expression patterns. A PROTAC targeting a liver protein may fail if its E3 ligase is poorly expressed in the liver. Expanding the E3 ligase toolbox beyond these two is critical for tissue-selective degradation. ### Off-Target Effects PROTACs can inadvertently degrade unintended proteins ("bystander degradation"), especially when the E3 ligase has broad substrate specificity. Proteome-wide degradation profiling and more selective warheads are needed to minimize these effects. ### Resistance Mechanisms Tumors can develop resistance to PROTACs through E3 ligase downregulation, mutations in the ubiquitin-proteasome pathway, or target protein mutations that disrupt ternary complex formation. Dual E3 ligase strategies and combination therapies are being explored to mitigate resistance. ### Manufacturing Complexity PROTAC synthesis requires multi-step chemical processes, purification of bifunctional molecules, and quality control of ternary complex formation. Scale-up for clinical and commercial production remains challenging and costly. ### Immunogenicity Degraded protein fragments (neoantigens) may trigger immune responses. While this could be therapeutically beneficial in some contexts, uncontrolled immunogenicity poses safety risks. Understanding the immunological consequences of widespread protein degradation is an active area of research. ## Innovations ### Emerging Innovations in PROTAC Therapeutics The PROTAC field is rapidly expanding beyond its original paradigm. New modalities are being developed to address limitations of classical PROTACs and to target entirely new categories of proteins, including extracellular and membrane-bound targets. Figure 12: Comprehensive landscape of PROTAC innovations organized into four quadrants: Element Innovations, Multidimensional Enhancements, Derived Concepts, and Novel Applications. ### Expanding the E3 Ligase Toolbox Chemical proteomics and fragment-based screening are enabling the discovery of new E3 ligase ligands. This three-stage pipeline maps ligandable hot spots, develops hit compounds through protein/cell-based screens, and validates biological applications against challenging targets like RAS. Notable new E3 ligases under investigation include KEAP1, RNF114, DCAF15, DCAF16 , and others. Figure 13: Three-stage chemical proteomics pipeline for E3 ligase discovery: mapping, hit development, and biological application. ### Emerging Degrader Modalities (Beyond PROTACs) Beyond classical PROTACs, several new degrader technologies are emerging: Molecular Glues are small molecules that stabilize interactions between E3 ligases and target proteins without requiring a linker. DUBTACs and RIPTACs represent chimeras that stabilize rather than degrade target proteins. These technologies expand the targeted protein degradation toolkit to cover a wider range of biological contexts. ### Lysosomal Targeting Chimeras (LYTACs) LYTACs extend targeted degradation to extracellular and membrane-bound proteins that are inaccessible to the proteasome. These antibody-based chimeras direct targets to lysosomal degradation via mannose-6-phosphate receptors (CI-M6PR) or asialoglycoprotein receptors (ASGPR). LYTACs have shown efficacy against EGFR, PD-L1, and other cell-surface targets. Figure 14: LYTAC mechanism showing antibody-based chimeras directing extracellular/membrane proteins to lysosomal degradation via CI-M6PR or ASGPR receptors. ### Autophagy-Based Degradation (AUTACs/ATTECs) AUTACs (autophagy-targeting chimeras) and ATTECs (autophagosome-tethering compounds) leverage the macroautophagy pathway to degrade targets. AUTACs use a guanine tag (K63 ubiquitin) to recruit autophagy machinery, while ATTECs directly tether targets to the autophagosome membrane protein LC3. A CMA (chaperone-mediated autophagy) based approach also enables targeted degradation through HSC70 recognition. Figure 15: AUTAC and ATTEC mechanisms using macroautophagy (i) and CMA-based degradation (ii) pathways. Target extracellular and membrane proteins via lysosomal degradation. Antibody-based, no proteasome needed. Effective against EGFR, PD-L1, and cell-surface oncoproteins. Small molecules that stabilize E3 ligase-target interactions without a linker. Simpler pharmacology than PROTACs. Thalidomide analogs (IMiDs) are the best-known examples. Leverage autophagy pathway instead of proteasome. Can degrade larger targets including protein aggregates and organelles. AUTACs use K63-ubiquitin tagging; ATTECs directly tether to LC3. ## Undruggable ### Targeting the "Undruggable" Perhaps the most transformative promise of PROTAC technology is its ability to target proteins previously considered "undruggable" by conventional pharmacology. These include oncogenic drivers without well-defined active sites, transcription factors that function through protein-protein interactions, and proteins where resistance mutations render traditional inhibitors ineffective. From inhibiting to eliminating: KRAS mutations drive ~25% of all human cancers. While direct KRAS inhibitors (sotorasib, adagrasib) have emerged, they face rapid resistance. PROTAC-based degraders can eliminate KRAS protein entirely, preventing compensatory pathway activation and overcoming acquired resistance mutations. Transcription factors like c-Myc (overexpressed in >50% of cancers), STAT3, and mutant p53 lack traditional drug binding sites. PROTACs can recruit E3 ligases to degrade these proteins by targeting any accessible surface, not just enzymatic active sites. This opens an entirely new therapeutic frontier. ### Overcoming Resistance PROTACs offer a "degrader advantage" against drug-resistant cancers. Because they don't depend on occupying a specific binding site, point mutations that confer resistance to inhibitors often don't affect PROTAC-mediated degradation. Dual E3 ligase engagement can further prevent resistance from ligase downregulation. ### Albumin-Based Delivery Albumin-binding PROTACs exploit the long half-life and tumor-accumulating properties of serum albumin to improve pharmacokinetics, extend circulation time, and enhance tumor delivery. This approach addresses the bioavailability challenges inherent to large PROTAC molecules. ## Ai ### AI and Multi-Omics in PROTAC Development Artificial intelligence and multi-omics data are accelerating PROTAC development at every stage, from target identification and E3 ligase selection to linker design and clinical trial optimization. These computational approaches are helping to overcome the traditionally empirical nature of PROTAC discovery. Figure 16: AI/multi-omics framework for E3 ligase selection: (a) multi-layered literature and computational importance scoring, (b) four-axis evaluation covering ligandability, expression profile, PPI, and structural/functional features. ### Computational Design & Chemoinformatics Machine learning models predict degradation efficiency, model ternary complex structures, and optimize linker length/rigidity. Tools like DeepPROTAC and PROTACable genome databases enable rational design. Molecular dynamics simulations help predict cooperative binding between POI and E3 ligase. ### Target & Ligase Selection via Omics Multi-omics datasets (TCGA, GTEx, HPA, single-cell RNA-seq) enable tissue-specific E3 ligase selection, ensuring the chosen ligase is expressed in the target tissue. Protein-protein interaction databases (BioGRID, IntAct, STRING) validate E3-substrate interactions computationally before experimental validation. ### Clinical Translation & Trial Design AI-driven approaches are optimizing clinical development: patient stratification using genomic biomarkers, adaptive trial designs that adjust dosing based on degradation biomarkers, and predictive models for toxicity and efficacy. These tools accelerate the path from bench to bedside. ## Conclusions ### Future Directions and Conclusions The clinical translation of PROTACs marks a significant transition in precision oncology, transforming targeted protein degradation from a largely conceptual strategy into a clinically validated therapeutic modality for treatment-resistant cancers. Early clinical candidates such as ARV-110, ARV-471, DT2216, and NX-2127 have collectively provided important lessons that extend beyond proof-of-concept efficacy, demonstrating that sustained target suppression can translate into meaningful clinical responses. Key future directions include: expanding the E3 ligase repertoire beyond CRBN and VHL, improving oral bioavailability through macrocyclization and prodrug strategies, developing combination therapies pairing PROTACs with immunotherapies, leveraging AI for rational degrader design, and establishing robust regulatory pathways for this new drug class. If these challenges are met, targeted protein degradation is poised to deliver durable therapeutic solutions across oncology and potentially immune and neurodegenerative diseases that have long resisted conventional pharmacological approaches. PROTACs are redefining therapeutic possibilities, offering a robust, flexible, and scalable framework for the future of precision medicine. ## Abbreviations ### Abbreviations